Investment Rating - The report maintains a "Buy" rating for both A and H shares of the company [7] Core Insights - The company achieved a revenue of 1.658 billion RMB and a net profit attributable to shareholders of 298 million RMB in 2025, reflecting a year-over-year change of -17.9% and +302.1% respectively, aligning with performance forecasts [1] - The company has seen a significant increase in new order amounts, with 4Q25 new orders reaching 960 million RMB, a year-over-year increase of 118.2%, indicating a recovery in domestic industry demand [1] - The company’s gross margin for 2025 was 20.7%, down 7.7 percentage points year-over-year, primarily due to the impact of low-quality orders from previous periods [2] - Operating cash flow improved significantly, with a net cash flow of 445 million RMB in 2025, up 31.2% year-over-year [2] - The company is expanding its technical capabilities, with a notable increase in project signings for antibody, small nucleic acid, ADC, and peptide drugs [3] - The overseas revenue reached 453 million RMB, accounting for 27.3% of total revenue, reflecting a year-over-year increase of 3.3% [4] - The company expects a recovery in domestic business in 2026, driven by improved market competitiveness and ongoing demand recovery [4] Summary by Sections Financial Performance - In 2025, the company reported a revenue of 1.658 billion RMB, a decrease of 17.87% from the previous year, while net profit attributable to shareholders was 298 million RMB, an increase of 302.08% [10] - The company forecasts net profits of 528 million RMB, 654 million RMB, and 848 million RMB for 2026, 2027, and 2028 respectively, with significant upward adjustments of 54% and 48% for 2026 and 2027 [5][11] Business Development - The company’s total order backlog was approximately 2.6 billion RMB, with new orders also around 2.6 billion RMB, indicating a year-over-year increase of 41.3% [1] - The company is enhancing its core business capabilities and expanding its facilities, which will support future business development [3] Market Outlook - The report anticipates continued growth in overseas revenue and a gradual recovery in domestic business, supported by the company’s strong market position in non-clinical safety evaluation [4] - The target prices for A and H shares are set at 45.83 RMB and 28.79 HKD respectively, based on a price-to-earnings ratio of 65x and 36x for 2026 [5]

Investment Rating - The report maintains a "Buy" rating for both A and H shares of the company [7] Core Views - The company achieved revenue and net profit of 1.658 billion and 298 million RMB in 2025, reflecting a year-over-year change of -17.9% and +302.1% respectively, aligning with performance forecasts [1] - The company has seen a significant increase in new orders, with 4Q25 new signed orders amounting to 960 million RMB, a year-over-year increase of 118.2%, indicating a recovery in domestic demand [1] - The overall order backlog for the company stands at approximately 2.6 billion RMB, up 18.2% year-over-year, with new signed orders also increasing by 41.3% year-over-year [1] Summary by Relevant Sections Financial Performance - The company's gross margin for 2025 was 20.7%, down 7.7 percentage points year-over-year, primarily due to the impact of low-quality orders from previous periods [2] - Operating cash flow for 2025 was 445 million RMB, reflecting a significant improvement of 31.2% year-over-year [2] Business Segments - Non-clinical research services generated revenue of 1.577 billion RMB, down 17.8% year-over-year, while overseas revenue in this segment grew by 3.1% [3] - Clinical services and others reported revenue of 72.83 million RMB, down 27.1% year-over-year, but the company is advancing its capabilities in biomarker detection for neurological diseases [3] - The experimental model supply segment saw a remarkable increase in revenue to 7.75 million RMB, up 754.5% year-over-year, indicating strong demand for diverse research needs [3] Geographic Revenue Breakdown - Overseas revenue reached 453 million RMB, up 3.3% year-over-year, accounting for 27.3% of total revenue, an increase of 5.6 percentage points year-over-year [4] - Domestic revenue was 1.204 billion RMB, down 23.8% year-over-year, primarily due to pressure from historical low-quality orders [4] Profit Forecast and Valuation - The company expects net profit attributable to shareholders to be 528 million, 654 million, and 848 million RMB for 2026, 2027, and 2028 respectively, with significant upward adjustments of 54% and 48% for 2026 and 2027 [5][11] - The report assigns a price-to-earnings ratio of 65x for A shares and 36x for H shares for 2026, with target prices set at 45.83 RMB and 28.79 HKD respectively [5]

Group 1 - On January 16, Zhaoyan New Drug experienced a decline of 1.84% with a trading volume of 673 million yuan, and the net financing buy was -7.46 million yuan [1] - As of January 16, the total balance of margin trading for Zhaoyan New Drug was 420 million yuan, with a financing balance of 415 million yuan, accounting for 1.56% of the circulating market value, which is below the 50th percentile level over the past year [1] - The company primarily engages in non-clinical safety evaluation services for drugs, with 95.59% of its main business revenue derived from non-clinical research services [1] Group 2 - As of September 30, the number of shareholders for Zhaoyan New Drug increased by 57.61% to 96,500, while the average circulating shares per person remained at 0 [2] - For the period from January to September 2025, Zhaoyan New Drug reported an operating income of 985 million yuan, a year-on-year decrease of 26.23%, while the net profit attributable to the parent company was 80.71 million yuan, reflecting a year-on-year increase of 214.79% [2] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]

Company Dynamics - Zhou Zhiwen, a major shareholder and actual controller of Zhaoyan New Drug (603127.SH), has announced a significant share reduction plan, potentially cashing out over 500 million yuan based on the current stock price [2] - Before the reduction, Zhou held 74,725,981 shares, accounting for 9.9704% of the total share capital, with a combined holding of 32.274% with his spouse, Feng Yuxia [2] - Following the announcement of the share reduction, Zhaoyan New Drug's stock dropped by 6.20% on December 30, closing at 34.80 yuan, indicating a potential cash-out of over 500 million yuan from the sale of 14.98 million shares [2] Industry Insights - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, gaining prominence in the capital market due to its assets in experimental monkeys [2] - The average market price of experimental monkeys has seen significant fluctuations, with prices rising from 13,800 yuan per monkey in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] - In November 2023, the price of experimental monkeys dropped to approximately 113,000 yuan each, reflecting a decrease of over 30% from the peak [3] - Despite a decline in revenue by 26.23% year-on-year to 985 million yuan in the first three quarters of 2025, Zhaoyan New Drug managed to achieve a net profit of 80.71 million yuan, indicating a recovery in performance [3] - As of December 29, 2025, Zhaoyan New Drug's stock price has increased by over 120% within the year [3] Shareholder Activity - Zhou Zhiwen has a history of share reductions, having sold a total of 14.11 million shares since November 2020, resulting in approximately 915 million yuan in cash [4]

Core Viewpoint - The stock price of Zhaoyan New Drug (603127.SH) surged due to the rebound in the market price of experimental monkeys, prompting major shareholder Zhou Zhiwen to announce a significant share reduction plan, potentially cashing out over 500 million yuan [1] Group 1: Shareholder Actions - Zhou Zhiwen plans to reduce his holdings by up to 14,980,000 shares, representing 20.0466% of his holdings and 1.99873% of the company's total share capital, within three months after the announcement [1] - Prior to the reduction, Zhou Zhiwen held 74,725,981 shares, accounting for 9.9704% of the company, with the couple's total holding at 32.274% [1] - Following the announcement of the share reduction, Zhaoyan New Drug's stock fell by 6.20% to a closing price of 34.80 yuan [1] Group 2: Company Overview - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, with a notable focus on experimental monkeys, which are critical for various research fields [2] - The price of experimental monkeys has fluctuated significantly, with the average market price rising from 13,800 yuan in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] Group 3: Financial Performance - In Q1 2024, Zhaoyan New Drug reported a revenue of 325 million yuan, a year-on-year decrease of 12.07%, and a net loss of 272 million yuan, attributed to a 284 million yuan loss from changes in the fair value of biological assets [3] - By the first three quarters of 2025, the company achieved a revenue of 985 million yuan, a year-on-year decrease of 26.23%, but turned a profit with a net income of 80.71 million yuan [3] - The stock price of Zhaoyan New Drug increased by over 120% throughout the year, reflecting a recovery in the market price of experimental monkeys [3] Group 4: Market Perception - Some market analysts argue that Zhaoyan New Drug primarily sells experimental services rather than monkeys, suggesting that monkey prices do not directly reflect the company's sustainable profitability [4] - Despite this, fluctuations in the value of experimental monkeys significantly impact the company's financial performance, leading to potential distortions in financial reporting [4]

Group 1 - The company held its second extraordinary general meeting of shareholders on December 5, 2025, with no resolutions being rejected [2][3] - The total number of shares with voting rights at the meeting was 746,174,300 shares after excluding shares held in the company's repurchase account [2] - The meeting was convened in accordance with the Company Law and the company's articles of association, with the chairman presiding over the meeting [3] Group 2 - The company approved several governance-related proposals, including the cancellation of the supervisory board and amendments to the articles of association [4][5] - All proposals related to the revision of governance systems and rules were passed unanimously [5][6] - The meeting was attended by all directors and supervisors, and the voting procedures were deemed valid [4][7] Group 3 - The company announced an expected related party transaction with Shengtong Intelligent Technology Co., Ltd., for a total amount not exceeding 16.5 million yuan for the year 2026 [11][12] - The transaction involves the provision of digital services and does not constitute a major asset reorganization [11] - The company had previously engaged in related transactions with Shengtong Intelligent amounting to 993.18 million yuan, which did not exceed 5% of the latest audited net assets [11][12] Group 4 - The company’s main business is non-clinical drug research services, and the collaboration with Shengtong Intelligent is expected to enhance operational efficiency and reduce costs [18] - The pricing for the services provided by Shengtong Intelligent will be based on a cost-plus model, ensuring alignment with market rates [16] - The independent directors and the board approved the related party transaction, confirming it aligns with the company's operational needs [19][20] Group 5 - The company plans to engage in daily related party transactions with Shuyitai Shen (Beijing) Biopharmaceutical Co., Ltd., which have been approved by the board [58][60] - These transactions are necessary for daily operations and are priced at market rates, ensuring no harm to the interests of the company or minority shareholders [65][66] - The company maintains its independence, with no reliance on these transactions for its main business or revenue [66] Group 6 - The company announced plans for entrusted financial management for 2026, with a maximum daily balance of 2 billion yuan for investments in low-risk financial products [69][72] - The purpose of the financial management is to enhance the efficiency of idle funds while ensuring the company's normal operations are not affected [71][78] - The board approved the financial management plan, which includes strict risk control measures [76][78] Group 7 - The company elected a new employee representative director, Li Ye, during the first meeting of the labor union committee on December 5, 2025 [79][80] - The new board will consist of 10 members, including 5 non-independent directors and 4 independent directors, complying with relevant regulations [79][80] - Li Ye has been with the company since 2007 and holds shares in the company, ensuring no conflicts of interest [80]

Core Viewpoint - Zhaoyan New Drug's stock price has experienced fluctuations, with a year-to-date increase of 67.23%, but recent declines in the short term [1][2] Company Overview - Zhaoyan New Drug Research Center Co., Ltd. was established on February 25, 1998, and listed on August 25, 2017. The company primarily focuses on non-clinical safety evaluation services for drugs and preclinical research services, with a revenue composition of 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from experimental model supply [1][2] Financial Performance - For the period from January to September 2025, Zhaoyan New Drug reported operating revenue of 985 million yuan, a year-on-year decrease of 26.23%. However, the net profit attributable to the parent company was 80.71 million yuan, reflecting a significant year-on-year increase of 214.79% [2] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders for Zhaoyan New Drug reached 96,500, an increase of 57.61% compared to the previous period. The average circulating shares per person remained at 0 [2] - Notable changes in institutional holdings include a decrease in shares held by Huabao Zhongzheng Medical ETF and new entries from Guangfa Small Cap Growth Mixed Fund and Guangfa Innovation Upgrade Mixed Fund [3]

Core Viewpoint - The stock of Zhaoyan New Drug has shown significant volatility, with a year-to-date increase of 70.06%, but recent declines in the short term raise concerns about its performance [1][2]. Group 1: Stock Performance - As of November 25, Zhaoyan New Drug's stock price increased by 2.02% to 28.23 CNY per share, with a trading volume of 162 million CNY and a turnover rate of 0.92%, resulting in a total market capitalization of 21.158 billion CNY [1]. - The stock has experienced a decline of 9.89% over the last five trading days, 15.48% over the last 20 days, and 14.14% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent occurrence on September 15 [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhaoyan New Drug reported a revenue of 985 million CNY, a year-on-year decrease of 26.23%, while the net profit attributable to shareholders increased by 214.79% to 80.706 million CNY [2]. - The company has distributed a total of 703 million CNY in dividends since its A-share listing, with 356 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Zhaoyan New Drug reached 96,500, an increase of 57.61% compared to the previous period [2]. - The top ten circulating shareholders include notable funds, with Huabao Zhongzheng Medical ETF holding 12.484 million shares, a decrease of 2.1693 million shares from the previous period, while new shareholders include Guangfa Small Cap Growth Mixed Fund [3].

Group 1 - The core viewpoint of the news highlights the stock performance and financial metrics of Zhaoyan New Drug, indicating a 99.22% increase in stock price year-to-date, with a recent slight decline in the last five and twenty trading days [1][2] - As of September 30, 2025, Zhaoyan New Drug reported a revenue of 985 million yuan, a year-on-year decrease of 26.23%, while the net profit attributable to shareholders increased by 214.79% to 80.71 million yuan [2] - The company has a market capitalization of 24.785 billion yuan and has seen significant trading activity, with a net inflow of 1.4684 million yuan from major funds [1] Group 2 - Zhaoyan New Drug's main business involves non-clinical safety evaluation services for drugs, accounting for 95.59% of its revenue, with clinical services and experimental model supply making up the remainder [1] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed in the last three years [3] - The number of shareholders increased by 57.61% to 96,500 as of September 30, 2025, indicating growing interest in the stock [2]

Core Viewpoint - Zhaoyan New Drug is a leading player in the domestic non-clinical safety evaluation industry, focusing on drug preclinical research services and sales of experimental animals and related products [1] Group 1: Business Performance - In Q3 2025, Zhaoyan New Drug reported revenue of 985 million yuan, ranking 9th in the industry, with the top competitor WuXi AppTec at 32.857 billion yuan [2] - The main business revenue from non-clinical research services was 639 million yuan, accounting for 95.59% of total revenue [2] - The net profit for the same period was 80.706 million yuan, ranking 15th in the industry [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 14.81%, lower than the industry average of 22.79% [3] - The gross profit margin for the same period was 21.55%, below the industry average of 37.70% [3] Group 3: Executive Compensation - The chairman, Feng Yuxia, received a salary of 2.5738 million yuan in 2024, a decrease of 635,600 yuan from 2023 [4] - The general manager, Gao Dapeng, earned 1.7384 million yuan in 2024, down 162,900 yuan from the previous year [4] Group 4: Shareholder Information - As of December 31, 2020, the number of A-share shareholders decreased by 6.87% to 16,700 [5] - The average number of circulating A-shares held per shareholder increased by 7.84% [5] Group 5: Market Outlook - Guolian Securities noted that the company's H1 2025 performance met expectations, with a stable growth in new orders [6] - The total order amount at the end of the reporting period was approximately 2.3 billion yuan, with new orders of about 1.02 billion yuan, reflecting a year-on-year growth of 13.3% [6] - Huaxi Securities adjusted revenue forecasts for 2025-2027 to 1.651 billion, 1.678 billion, and 1.762 billion yuan, respectively [7]